A Figure J. Limited coronal CTs of the paranasa l sinuses show opacification (arrows) of the right ethmoid air cell (A) and the right sphenoid sinus (B) .
A 67-yea r-old woma n had been treated for 6 month s with antihistamines, nasal steroids, and antibiotics for suspec ted sinusitis. When she continued to com plain of progressive headaches, right-sided epiph ora, and anos mia, limited computed tomograph y (CT) of the paranasal sinuses was obtained (figure I). A diagno sis of right-sided ethmo id sinusitis was made, and the patient was refe rred to us for endosc opic sinus surgery . Find ings on our review of the patient's sinus CTs were not consistent with the range and severi ty of her symptoms, so we obtained further imaging.
CT of the orbits detected the presence of a mass that extended from the right ethmo id sinuses into the orbital apex, anterior cranial fossa, right frontal lobe, and sphenoid sinus (figure 2). Findi ngs on endoscopic biopsy were consiste nt with squamous ce ll carcinoma (SCC) . The patient underwent a craniofacial resec tion and postoperative radiotherapy.
Malignant tumors of the ethmo id sinus account for a low percentage of head and neck cancers. When they do occur, SCC is the most common histologic subtype, followe d by adenoca rcinoma, adenoid cys tic carci noma, and several others .I Like other sinonasal malignancies, SCC of the ethmo id sinus is ofte n diagnosed at a relatively late stage. Thi s delay in diagnosis is largely attributable to the nonspecific nature of early symptoms, which are often cons istent with benign nasal and sinus obstructions. The American Joint Committ ee on Cancer Staging? has class ified the tum or compo nent of sinonasal SCC thusly:
• Tl : The tumor is confined to a single subsite with or with out bony invasion. • T2:Th e tumor involves 2 subsites or an adjacent area of the nasoethmoid complex with or without bony invasion. Because the SCC in our patient extended into the right orbital apex , the anterior cranial fossa, the brain, and the sphenoid sinus, it was staged as a T4b lesion.
The treatment ofSCCs of the ethmoid sinus has evolv ed in a manner consistent with the evolution of the treatment of SCCs in other structure-sensitive areas of the head and neck. Surgical resection and intensit y-modulated radiothe rapy (IMRT) are now used in a complementary fashion for local tumor control. Moreover, a variety of cisplatin-based chemotherapeutic protocols can be added to the treatm ent regimen for patient s with known or suspected regional or ENT3.6F Nasopharyngoscope distant metastatic disease. IMRT is especially useful for patients with tumor-p ositive surgica l margins, recurrent disease, and/or locally advanced disease. Given the rarity of ethmoid sinus tumor s, treatmentspecific and overall outcomes data are derived mostly from small cohort studies, and results vary somewhat. The overall 5-year survival rate for ethmoid carcinomas of all histologic subtypes appears to be as high as 50 to 60%,3 although several studie s have report ed much lower rates of 5-year survival for patients with SCc. For example, Uchida et al reported a 5-year survival rate of only 25% among 20 patients with ethmoid SCC who were treated with either radiotherapy plus surgery or radiotherapy alone.I Dulguerov et al reported a 5-year surviv al rate of 48% among 220 patients with ethmo id carcinoma, but they did not distin guish among multiple histologic subtype s.' They also suggested that survival was better among patients who underwent surgery or surgery plus radiation rather than radiation alone. Finally, they recommended orbit enucle ation rather than preservation in the setting of orbital invasion.
The increasing availability of IMRT and our experience with it may well have a significant impact on improving local control and perh aps survival as more optimal doses of radiation are delivered to the desired area far more precisely than before.
